A mitochondrial ROS pathway controls matrix metalloproteinase 9 levels and invasive properties in RAS-activated cancer cells.


Journal

The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646

Informations de publication

Date de publication:
02 2019
Historique:
received: 14 04 2018
revised: 29 08 2018
accepted: 28 09 2018
pubmed: 4 10 2018
medline: 9 8 2019
entrez: 4 10 2018
Statut: ppublish

Résumé

Matrix metalloproteinases (MMPs) are tissue-remodeling enzymes involved in the processing of various biological molecules. MMPs also play important roles in cancer metastasis, contributing to angiogenesis, intravasation of tumor cells, and cell migration and invasion. Accordingly, unraveling the signaling pathways controlling MMP activities could shed additional light on cancer biology. Here, we report a molecular axis, comprising the molecular adaptor hydrogen peroxide-inducible clone-5 (HIC-5), NADPH oxidase 4 (NOX4), and mitochondria-associated reactive oxygen species (mtROS), that regulates MMP9 expression and may be a target to suppress cancer metastasis. We found that this axis primarily downregulates mtROS levels which stabilize MMP9 mRNA. Specifically, HIC-5 suppressed the expression of NOX4, the source of the mtROS, thereby decreasing mtROS levels and, consequently, destabilizing MMP9 mRNA. Interestingly, among six cancer cell lines, only EJ-1 and MDA-MB-231 cells exhibited upregulation of NOX4 and MMP9 expression after shRNA-mediated HIC-5 knockdown. In these two cell lines, activating RAS mutations commonly occur, suggesting that the HIC-5-mediated suppression of NOX4 depends on RAS signaling, a hypothesis that was supported experimentally by the introduction of activated RAS into mammary epithelial cells. Notably, HIC-5 knockdown promoted lung metastasis of MDA-MB-231 cancer cells in mice. The tumor growth of HIC-5-silenced MDA-MB-231 cells at the primary sites was comparable to that of control cells. Consistently, the invasive properties of the cells, but not their proliferation, were enhanced by the HIC-5 knockdown in vitro. We conclude that NOX4-mediated mtROS signaling increases MMP9 mRNA stability and affects cancer invasiveness but not tumor growth.

Identifiants

pubmed: 30281903
doi: 10.1111/febs.14671
pmc: PMC7379617
doi:

Substances chimiques

Intracellular Signaling Peptides and Proteins 0
KRAS protein, human 0
LIM Domain Proteins 0
RNA, Messenger 0
RNA, Small Interfering 0
Reactive Oxygen Species 0
TGFB1I1 protein, human 0
NADPH Oxidase 4 EC 1.6.3.-
NOX4 protein, human EC 1.6.3.-
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
MMP9 protein, human EC 3.4.24.35
Matrix Metalloproteinase 9 EC 3.4.24.35
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Editorial Research Support, Non-U.S. Gov't

Langues

eng

Pagination

459-478

Informations de copyright

© 2018 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Références

Mol Biol Cell. 2003 Mar;14(3):1158-71
pubmed: 12631731
J Cell Biochem. 2004 Feb 15;91(3):633-45
pubmed: 14755691
Circ Res. 2009 Jul 31;105(3):249-59
pubmed: 19574552
J Biol Chem. 2007 May 18;282(20):14708-18
pubmed: 17369262
FASEB J. 2014 Jan;28(1):485-94
pubmed: 24115050
Cancer Biol Ther. 2010 Aug 1;10(3):223-31
pubmed: 20523116
Semin Cell Dev Biol. 2008 Feb;19(1):61-8
pubmed: 17693104
Cancer Sci. 2016 Jul;107(7):963-71
pubmed: 27094710
Mol Cell Biol. 2001 Aug;21(16):5332-45
pubmed: 11463817
Nat Rev Cancer. 2002 Mar;2(3):161-74
pubmed: 11990853
Cancer Res. 2004 Oct 15;64(20):7464-72
pubmed: 15492271
Cell Death Dis. 2015 Jan 22;6:e1619
pubmed: 25611393
Cell Signal. 2006 Jan;18(1):69-82
pubmed: 15927447
Genes Dev. 2001 Jan 1;15(1):50-65
pubmed: 11156605
Clin Cancer Res. 1999 Jul;5(7):1905-17
pubmed: 10430098
Circ Res. 2010 Apr 16;106(7):1253-64
pubmed: 20185797
J Clin Invest. 2016 Sep 1;126(9):3403-16
pubmed: 27525436
Nat Rev Drug Discov. 2014 Dec;13(12):904-27
pubmed: 25376097
Mol Cell Biol. 2003 Jul;23(14):4901-16
pubmed: 12832476
J Cell Biol. 2008 Jun 30;181(7):1129-39
pubmed: 18573911
Mol Biol Cell. 2009 Jan;20(1):218-32
pubmed: 18946086
Mol Cell Biol. 2002 Apr;22(7):2111-23
pubmed: 11884599
J Biol Chem. 2014 Jun 27;289(26):18270-8
pubmed: 24831009
Int J Biochem Cell Biol. 2016 Aug;77(Pt A):91-101
pubmed: 27267661
Cancer Metastasis Rev. 2006 Mar;25(1):9-34
pubmed: 16680569
Dis Model Mech. 2015 Dec;8(12):1579-89
pubmed: 26449263
Cancer Metastasis Rev. 2006 Dec;25(4):695-705
pubmed: 17160708
J Biol Chem. 2013 Mar 8;288(10):6835-48
pubmed: 23329835
Mol Biol Cell. 2011 Feb 1;22(3):327-41
pubmed: 21148292
J Biol Chem. 2012 Nov 9;287(46):38854-65
pubmed: 23007394
Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33
pubmed: 17318226
J Cell Mol Med. 2011 Jun;15(6):1254-65
pubmed: 21418514
Free Radic Biol Med. 2012 Oct 1;53(7):1489-99
pubmed: 22728268
Oncogene. 2007 Sep 6;26(41):5991-6001
pubmed: 17369841
Circ Res. 2010 Jul 9;107(1):106-16
pubmed: 20448215
Biochem Biophys Res Commun. 2014 Jan 17;443(3):821-7
pubmed: 24342608
Free Radic Biol Med. 2004 Sep 15;37(6):768-84
pubmed: 15304253
Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14385-90
pubmed: 19706525
Free Radic Res. 2011 Jun;45(6):672-80
pubmed: 21391894
Mol Cell Biol. 2010 Jul;30(14):3553-68
pubmed: 20457808
Mitochondrion. 2013 May;13(3):246-53
pubmed: 22960576
J Biol Chem. 2006 Aug 4;281(31):22048-61
pubmed: 16737959
Biochim Biophys Acta. 2010 Jan;1803(1):39-54
pubmed: 19800373
Neurotoxicology. 2018 Jul;67:296-304
pubmed: 29966605
Biochim Biophys Acta. 2013 Jan;1833(1):213-24
pubmed: 22575682
J Biol Chem. 1994 Oct 28;269(43):26767-74
pubmed: 7929412
Int J Cell Biol. 2012;2012:426138
pubmed: 22145007
Biochem J. 2007 Aug 15;406(1):105-14
pubmed: 17501721
J Biol Chem. 2001 Feb 16;276(7):4588-96
pubmed: 11092892
Exp Hematol. 2003 Nov;31(11):1007-14
pubmed: 14585362
Biochim Biophys Acta. 2005 May 25;1755(1):37-69
pubmed: 15907591

Auteurs

Kazunori Mori (K)

Division of Cancer Cell Biology, Department of Pharmaceutical Sciences, Showa University School of Pharmacy, Tokyo, Japan.

Tetsu Uchida (T)

Division of Cancer Cell Biology, Department of Pharmaceutical Sciences, Showa University School of Pharmacy, Tokyo, Japan.

Toshihiko Yoshie (T)

Division of Cancer Cell Biology, Department of Pharmaceutical Sciences, Showa University School of Pharmacy, Tokyo, Japan.

Yuko Mizote (Y)

Division of Cancer Cell Biology, Department of Pharmaceutical Sciences, Showa University School of Pharmacy, Tokyo, Japan.

Fumihiro Ishikawa (F)

Division of Cancer Cell Biology, Department of Pharmaceutical Sciences, Showa University School of Pharmacy, Tokyo, Japan.

Masato Katsuyama (M)

Radioisotope Center, Kyoto Prefectural University of Medicine, Japan.

Motoko Shibanuma (M)

Division of Cancer Cell Biology, Department of Pharmaceutical Sciences, Showa University School of Pharmacy, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH